AstraZeneca’s agreement with Eccogene is worth up to $2.01bn in total, with Eccogene receiving $185mn as an upfront payment to give exclusive global rights, excluding China, to the development ...
Nov 1 (Reuters) - AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to speed up the development of ...
Under the Collaboration Agreement, AstraZeneca will leverage Cellectis ... trading platforms and financial exchanges. Sign up for our newsletter to get the latest on the transformative forces ...
Notably, AstraZeneca (AZN) also entered a significant licensing agreement to accelerate its obesity pipeline and bring competition to Novo Nordisk's Wegovy and Eli Lilly's Zepbound in a fast ...
Anglo-Swedish drug company AstraZeneca announced that it signed a licensing agreement with Eccogene, a Chinese firm for oral medicines which will treat diabetes and obesity on Thursday, 9 November ...
Under the agreement, AstraZeneca would leverage Quell's proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock, to develop autologous multi-modular ...
AstraZeneca has signed an agreement whereby it will outsource most ofits information technology operations to IBM, in a deal worth $1.7 billion over seven years. As part of the agreement, 1,200 ...
“Under the terms of the collaboration agreement, AstraZeneca will leverage the Cellectis proprietary gene editing technologies and manufacturing capabilities, to design novel cell and gene ...
Under the Collaboration Agreement, AstraZeneca will leverage Cellectis' gene editing technologies and manufacturing capabilities to design cell and gene therapy candidate products. AstraZeneca ...
Under the terms of the Collaboration Agreement, AstraZeneca will leverage Cellectis’ proprietary gene editing technologies and manufacturing capabilities to design novel cell and gene therapy ...
